Related Experiment Video
Updated: May 19, 2026

Preoxygenation Techniques for Tracheal Intubation in Critically Ill Adults Utilizing Oxygen Mask and Noninvasive Ventilation
Published on: December 5, 2025
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a
Shenglan Tan1,2, Yang Sun3, Yixin Peng1,2
1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R China.
Objectives:
While immune checkpoint inhibitors (ICIs) continue to transform the neoadjuvant treatment, its association with postoperative acute hypoxemic respiratory failure (AHRF) remains unexplored. This study aims to assess the association between neoadjuvant immunochemotherapy (nICT) and postoperative AHRF risk following thoracic tumour surgeries and identify the risk subgroups.
Methods:
This retrospective two-centre cohort study included 327 patients receiving nICT (n = 167) or neoadjuvant immunochemotherapy (nCT, n = 160) before thoracic tumour surgeries from December 2017 to June 2023. Data were analysed by using the propensity score matching (PSM) and multivariable logistic regressions. Subgroup and sensitivity analyses were performed to test the stability of the conclusions.
Results:
The nICT group demonstrated significantly higher postoperative AHRF incidence than the nCT group (19.8% vs. 8.1%, p = 0.002). The inverse probability-weighting model (IPTW) confirmed elevated AHRF risk associated with nICT compared to nCT (OR = 2.41, 95% CI: 1.2-4.82). In patients with non-small cell lung cancer (NSCLC), the binary logistic regression analysis showed that the history of nICT was significantly associated with postoperative AHRF (OR = 4.12, 95% CI: 1.15-14.8) in patients with NSCLC. Subgroup analyses revealed elevated AHRF risks with nICT versus nCT in patients with time interval between neoadjuvant therapy and surgery within 42 days (OR = 6.68, 95% CI: 1.24-35.98), those with squamous cell carcinoma (SCC) (OR = 3.64, 95% CI: 1.41-9.44), and those who did not achieve pathologic complete response (non-pCR) (OR = 2.82, 95% CI: 1.14-6.98).
Conclusions:
nICT was associated with increased postoperative AHRF risk in thoracic surgical patients, necessitating rigorous perioperative monitoring.
Related Concept Videos
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
COPD: Management Using Bronchodilators and Corticosteroids
Endoscopic Studies II: Thoracocentesis
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
